Opioid-Related Adverse Drug Events Associated With Worse Patient, Cost Outcomes
Adjusted risks for absolute mortality were 2.9% higher in individuals experiencing ≥1 vs no adverse events.
Adverse events associated with opioids administered for the management of surgery- and endoscopy-related pain may be associated with worse cost and patient outcomes, including higher inpatient mortality, higher rate of 30-day rehospitalization, and greater opioid use, according to a study published in JAMA Surgery.
In this retrospective study, investigators examined demographic and clinical data as well as information related to opioid intake (ie, type of opioid, opioid dose, and inpatient treatment duration) for 135,379 inpatients (≥18 years old; 67.5% women) who had undergone surgery or an endoscopic procedure between January 2013 and September 2015 and who had received ≥1 opioid.
Incidence of opioid-related adverse drug events was the primary outcome. Associations between opioid-related adverse events and patient outcomes (eg, mortality, discharge to another facility), as well as cost outcomes (eg, length of hospital stay, 30-day readmission), were evaluated.
A total of 14,386 patients (10.6%) reported ≥1 opioid-related adverse event. These events were more prevalent in patients who were white, older, men, and Medicare beneficiaries; in those who presented with comorbidities; and in those who had undergone endoscopic procedures, open thoracic procedures (37.6%), and open abdominal surgeries. The majority of patients who reported adverse events only experienced 1 event (73%), and 55.8% and 37.3% experienced at least 1 moderate or 1 severe event, respectively. The most common adverse events were respiratory, as well as nausea/vomiting and bradycardia.